SK281787B6 - Hydroxyestery rapamycínu, ich použitie, farmaceutická kompozícia s ich obsahom a spôsob ich prípravy - Google Patents
Hydroxyestery rapamycínu, ich použitie, farmaceutická kompozícia s ich obsahom a spôsob ich prípravy Download PDFInfo
- Publication number
- SK281787B6 SK281787B6 SK1330-96A SK133096A SK281787B6 SK 281787 B6 SK281787 B6 SK 281787B6 SK 133096 A SK133096 A SK 133096A SK 281787 B6 SK281787 B6 SK 281787B6
- Authority
- SK
- Slovakia
- Prior art keywords
- rapamycin
- carbon atoms
- ester
- pharmaceutically acceptable
- alkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims description 93
- 229960002930 sirolimus Drugs 0.000 title claims description 93
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims description 76
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 238000000034 method Methods 0.000 title abstract description 18
- 230000008569 process Effects 0.000 title description 2
- -1 silylethyl Chemical group 0.000 claims abstract description 43
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 33
- 239000001257 hydrogen Substances 0.000 claims abstract description 31
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 20
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- 125000004276 dioxalanyl group Chemical group 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000004849 alkoxymethyl group Chemical group 0.000 claims abstract description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims abstract description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 64
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- HKKBKIDDTRVRHW-UHFFFAOYSA-N 3-methyl-1,5-dioxaspiro[5.5]undecane-3-carboxylic acid Chemical compound O1CC(C)(C(O)=O)COC11CCCCC1 HKKBKIDDTRVRHW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000005917 acylation reaction Methods 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 230000010933 acylation Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960004275 glycolic acid Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- WZEWDEAIHCUMKY-UHFFFAOYSA-N 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid Chemical compound CC1(C)OCC(C)(C(O)=O)CO1 WZEWDEAIHCUMKY-UHFFFAOYSA-N 0.000 claims description 2
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 claims description 2
- XUUUBCBLTSCBMO-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxane-5-carboxylic acid Chemical compound CC1(C)OCC(C(O)=O)CO1 XUUUBCBLTSCBMO-UHFFFAOYSA-N 0.000 claims description 2
- JGOQLTUMDGDSPK-UHFFFAOYSA-N 2,2-dimethyl-3-(oxan-2-yloxy)propanoic acid Chemical compound OC(=O)C(C)(C)COC1CCCCO1 JGOQLTUMDGDSPK-UHFFFAOYSA-N 0.000 claims description 2
- VJMAPBSIOGSYCR-UHFFFAOYSA-N 2,2-dimethyl-5-(2-trimethylsilylethoxymethyl)-1,3-dioxane-5-carboxylic acid Chemical compound CC1(C)OCC(COCC[Si](C)(C)C)(C(O)=O)CO1 VJMAPBSIOGSYCR-UHFFFAOYSA-N 0.000 claims description 2
- JWBQDXPJNGBSDC-UHFFFAOYSA-N 2-(oxan-2-yloxy)acetic acid Chemical compound OC(=O)COC1CCCCO1 JWBQDXPJNGBSDC-UHFFFAOYSA-N 0.000 claims description 2
- RDFQSFOGKVZWKF-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanoic acid Chemical compound OCC(C)(C)C(O)=O RDFQSFOGKVZWKF-UHFFFAOYSA-N 0.000 claims description 2
- ULMZOZMSDIOZAF-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)propanoic acid Chemical compound OCC(CO)C(O)=O ULMZOZMSDIOZAF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 64
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 11
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- 229940121375 antifungal agent Drugs 0.000 abstract description 3
- 230000000843 anti-fungal effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 125000005741 alkyl alkenyl group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 239000000203 mixture Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 239000012634 fragment Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 230000000144 pharmacologic effect Effects 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 238000010998 test method Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 208000009386 Experimental Arthritis Diseases 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000006241 alcohol protecting group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FQQYOXPFBMYCPO-AURGRMCHSA-N C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](O)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](O)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 FQQYOXPFBMYCPO-AURGRMCHSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003350 kerosene Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- CXUAEBDTJFKMBV-UHFFFAOYSA-N 1-(chloromethyl)-2,3,4,5,6-pentamethylbenzene Chemical compound CC1=C(C)C(C)=C(CCl)C(C)=C1C CXUAEBDTJFKMBV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Domestic Plumbing Installations (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/229,261 US5362718A (en) | 1994-04-18 | 1994-04-18 | Rapamycin hydroxyesters |
| PCT/US1995/004603 WO1995028406A1 (en) | 1994-04-18 | 1995-04-14 | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK133096A3 SK133096A3 (en) | 1997-04-09 |
| SK281787B6 true SK281787B6 (sk) | 2001-07-10 |
Family
ID=22860462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1330-96A SK281787B6 (sk) | 1994-04-18 | 1995-04-14 | Hydroxyestery rapamycínu, ich použitie, farmaceutická kompozícia s ich obsahom a spôsob ich prípravy |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US5362718A (es) |
| EP (3) | EP0763039B3 (es) |
| JP (1) | JP3725901B2 (es) |
| KR (1) | KR100330800B1 (es) |
| CN (1) | CN1059905C (es) |
| AT (3) | ATE350384T1 (es) |
| BR (1) | BR9507323A (es) |
| CA (1) | CA2187024C (es) |
| CY (2) | CY2378B1 (es) |
| CZ (1) | CZ284567B6 (es) |
| DE (3) | DE122008000023I1 (es) |
| DK (2) | DK0763039T3 (es) |
| ES (3) | ES2191704T7 (es) |
| FR (1) | FR08C0018I2 (es) |
| HK (2) | HK1011352A1 (es) |
| HU (1) | HU225915B1 (es) |
| IL (1) | IL113179A (es) |
| LU (1) | LU91438I2 (es) |
| LV (1) | LV13038B (es) |
| MX (1) | MX9604694A (es) |
| NL (1) | NL300348I2 (es) |
| NZ (1) | NZ283988A (es) |
| PL (1) | PL183178B1 (es) |
| PT (2) | PT1266899E (es) |
| RU (1) | RU2134267C1 (es) |
| SI (2) | SI0763039T1 (es) |
| SK (1) | SK281787B6 (es) |
| TW (1) | TW275631B (es) |
| WO (1) | WO1995028406A1 (es) |
| ZA (1) | ZA953090B (es) |
Families Citing this family (329)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US8790391B2 (en) | 1997-04-18 | 2014-07-29 | Cordis Corporation | Methods and devices for delivering therapeutic agents to target vessels |
| US6984635B1 (en) * | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| TWI256395B (en) * | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| PT1318837E (pt) | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
| JP2004509898A (ja) | 2000-09-19 | 2004-04-02 | ワイス | 水溶性ラパマイシンエステル |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US20060222756A1 (en) * | 2000-09-29 | 2006-10-05 | Cordis Corporation | Medical devices, drug coatings and methods of maintaining the drug coatings thereon |
| US20070276475A1 (en) * | 2000-09-29 | 2007-11-29 | Llanos Gerard H | Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon |
| MXPA03002871A (es) | 2000-09-29 | 2004-12-06 | Johnson & Johnson | Dispositivos medicos recubiertos. |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| WO2002044418A2 (en) | 2000-11-28 | 2002-06-06 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2269603B1 (en) | 2001-02-19 | 2015-05-20 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with exemestane |
| IL157898A0 (en) * | 2001-04-06 | 2004-03-28 | Wyeth Corp | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| MXPA04001524A (es) | 2001-08-22 | 2004-05-31 | Wyeth Corp | 29-enoles de rapamicina. |
| WO2003018574A1 (en) * | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin dialdehydes |
| US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US7682387B2 (en) | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| PL216224B1 (pl) | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
| US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| CN1652757B (zh) | 2002-05-16 | 2012-02-08 | 诺瓦提斯公司 | Edg受体结合剂在癌症中的应用 |
| KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
| WO2003099192A2 (en) | 2002-05-27 | 2003-12-04 | Novartis Ag | Bis-aromatic alkanols |
| US7026330B2 (en) * | 2002-05-30 | 2006-04-11 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| EP2277898A3 (en) | 2002-07-16 | 2011-06-01 | Biotica Technology Limited | Rapamycin analogues |
| DK1553940T3 (da) | 2002-07-30 | 2008-06-02 | Wyeth Corp | Patenterale formuleringer indeholdende en rapamycin-hydroxyester |
| WO2004014222A2 (en) * | 2002-08-12 | 2004-02-19 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| CN100415233C (zh) * | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
| US20070078513A1 (en) * | 2002-09-18 | 2007-04-05 | Medtronic Vascular, Inc. | Controllable drug releasing gradient coatings for medical devices |
| TWI376363B (en) | 2002-09-24 | 2012-11-11 | Novartis Ag | Pharmaceutical combination for treating demyelinating disease |
| WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| EP2517730A3 (en) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| KR20060006058A (ko) * | 2003-04-22 | 2006-01-18 | 와이어쓰 | 항신생물성 배합물 |
| US20040213757A1 (en) * | 2003-04-23 | 2004-10-28 | Wyeth Holdings Corporation | Water soluble wortmannin derivatives |
| US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| EP1636360A4 (en) * | 2003-06-03 | 2006-11-08 | Cell Genesys Inc | COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| WO2005010010A1 (en) * | 2003-07-16 | 2005-02-03 | Wyeth | Cci-779 isomer c |
| RU2345772C2 (ru) * | 2003-07-25 | 2009-02-10 | Уайт | Лиофилизированные композиции cci-779 |
| RU2339639C2 (ru) * | 2003-08-07 | 2008-11-27 | Уайт | Региоселективный синтез cci-779 |
| JP2007504226A (ja) * | 2003-09-03 | 2007-03-01 | ワイス | 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物 |
| AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| ES2298861T3 (es) * | 2004-01-08 | 2008-05-16 | Wyeth | Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779. |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| BRPI0509854A (pt) | 2004-04-14 | 2007-10-23 | Wyeth Corp | composto, métodos para a preparação regio-especìfica de um 42-éster de rapamicina ou 42-éster de prolina-rapamicina e para a preparação de um 42-éster de prolina-rapamicina, composição, e, produto |
| AU2005238431A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
| US7445916B2 (en) * | 2004-04-14 | 2008-11-04 | Wyeth | Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| CA2562164A1 (en) * | 2004-04-27 | 2005-11-10 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| CA2573656A1 (en) * | 2004-07-13 | 2006-02-16 | Cell Genesys, Inc. | Aav vector compositions and methods for enhanced expression of immunoglobulins using the same |
| US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| SV2006002188A (es) * | 2004-08-10 | 2006-03-15 | Wyeth Corp | Derivados de cci - 779 y metodos para su preparacion ref. am-101759salvo |
| GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| KR20070070184A (ko) * | 2004-10-28 | 2007-07-03 | 와이어쓰 | 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도 |
| US20080221660A1 (en) * | 2004-10-28 | 2008-09-11 | Medtronic Vascular, Inc. | Platelet Gel for Treatment of Aneurysms |
| US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| AU2006210572B2 (en) | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| US7442707B2 (en) * | 2005-02-09 | 2008-10-28 | Wyeth | CCI-779 polymorph and use thereof |
| KR20070104908A (ko) * | 2005-02-15 | 2007-10-29 | 와이어쓰 | 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물 |
| GB0503936D0 (en) * | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
| JP2008531686A (ja) * | 2005-03-02 | 2008-08-14 | ワイス | ラパマイシンの精製 |
| BRPI0607390A2 (pt) * | 2005-03-02 | 2017-08-22 | Wyeth Corp | Processo para recuperar cci-779 de licores mâe |
| GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| KR20070116868A (ko) | 2005-03-11 | 2007-12-11 | 바이오티카 테크놀로지 리미티드 | ３９데스메톡시라파마이신 및 그 유사체의 의학적 용도 |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| CA2604393A1 (en) * | 2005-04-15 | 2006-10-26 | Schering Corporation | Methods and compositions for treating or preventing cancer |
| US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
| US20070004767A1 (en) * | 2005-06-30 | 2007-01-04 | Gutmann David H | Methods for treating neurofibromatosis 1 |
| US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| CN105233349B (zh) | 2005-07-15 | 2019-06-18 | 胶束技术股份有限公司 | 包含受控形态的药物粉末的聚合物涂层 |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| ES2468240T3 (es) | 2005-08-19 | 2014-06-16 | Endocyte, Inc. | Conjugados de ligando de múltiples fármacos |
| JP2009505727A (ja) | 2005-08-25 | 2009-02-12 | メドトロニック ヴァスキュラー インコーポレイテッド | 医療機器及びそのコーティングとして有益な一酸化窒素放出生分解性ポリマー |
| ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
| US7538119B2 (en) * | 2005-11-04 | 2009-05-26 | Wyeth | 41-Methoxy isotope labeled rapamycin 42-ester |
| AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
| CN101321770A (zh) * | 2005-12-07 | 2008-12-10 | 惠氏公司 | 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法 |
| JP2009518413A (ja) * | 2005-12-07 | 2009-05-07 | ワイス | 精製結晶性ｃｃｉ−７７９を調製するためのプロセス |
| JP2009518648A (ja) * | 2005-12-07 | 2009-05-07 | ワイス | 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法 |
| CA2637255C (en) * | 2006-02-02 | 2018-06-12 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders |
| US20070203169A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same |
| WO2007103348A2 (en) * | 2006-03-07 | 2007-09-13 | Wyeth | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| CA2650590C (en) | 2006-04-26 | 2018-04-03 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
| GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| AU2007315790A1 (en) * | 2006-06-30 | 2008-05-08 | Interface Biologics, Inc. | Bioresponsive polymers |
| US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
| US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
| WO2008033956A2 (en) | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| US8067055B2 (en) | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
| US20080097591A1 (en) * | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
| US7691402B2 (en) * | 2006-11-06 | 2010-04-06 | Medtronic Vascular, Inc. | Block biodegradable copolymers for medical devices |
| US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP2090580B1 (en) * | 2006-11-27 | 2014-06-04 | Terumo Kabushiki Kaisha | Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CN101711137B (zh) | 2007-01-08 | 2014-10-22 | 米歇尔技术公司 | 具有可生物降解层的支架 |
| US7753962B2 (en) * | 2007-01-30 | 2010-07-13 | Medtronic Vascular, Inc. | Textured medical devices |
| WO2008094181A2 (en) * | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| US7815927B2 (en) * | 2007-03-08 | 2010-10-19 | Medtronic Vascular, Inc. | Terpolymers for controlled release of bioactive agents from implantable medical devices |
| US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
| EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
| US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US20080306581A1 (en) * | 2007-06-07 | 2008-12-11 | Medtronic Vascular, Inc. | Streamlined Stents |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| US8852620B2 (en) | 2007-07-20 | 2014-10-07 | Medtronic Vascular, Inc. | Medical devices comprising polymeric drug delivery systems with drug solubility gradients |
| US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
| US20090043378A1 (en) * | 2007-08-10 | 2009-02-12 | Medtronic Vascular, Inc. | Biocompatible Polymer System for Extended Drug Release |
| US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
| KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
| WO2009043174A1 (en) | 2007-10-05 | 2009-04-09 | Interface Biologics Inc. | Oligofluorinated cross-linked polymers and uses thereof |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CA2703017C (en) | 2007-10-19 | 2017-04-25 | Roseita Esfand | Self-eliminating coatings |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| US8921642B2 (en) * | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
| US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
| US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
| US20090240323A1 (en) * | 2008-03-20 | 2009-09-24 | Medtronic Vascular, Inc. | Controlled Degradation of Magnesium Stents |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| CN102083397B (zh) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | 具有生物可吸收层的支架 |
| US20090269480A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents |
| US20090297576A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of PAR-1 Antagonists to Treat Vascular Complications |
| US20090299464A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends |
| KR20180128078A (ko) | 2008-06-17 | 2018-11-30 | 와이어쓰 엘엘씨 | Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
| KR20170081755A (ko) | 2008-06-20 | 2017-07-12 | 노파르티스 아게 | 다발성 경화증을 치료하기 위한 소아용 조성물 |
| WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| CN101676291B (zh) * | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| WO2010040064A1 (en) * | 2008-10-03 | 2010-04-08 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US20100092534A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Combination Local Delivery Using a Stent |
| US20100092535A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Nanoporous Drug Delivery System |
| PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| US20100131051A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s) |
| US20100131001A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Targeted Drug Delivery for Aneurysm Treatment |
| US20100152832A1 (en) * | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta |
| ES2531831T3 (es) | 2008-12-18 | 2015-03-20 | Novartis Ag | Forma polimórfica del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxilico |
| MX2011006609A (es) | 2008-12-18 | 2011-06-30 | Novartis Ag | Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-m etil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico . |
| US8486930B2 (en) | 2008-12-18 | 2013-07-16 | Novartis Ag | Salts |
| US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
| US20100198338A1 (en) * | 2009-01-30 | 2010-08-05 | Medtronic Vascular, Inc., A Delaware Corporation | Hydrogen Sulfide Donating Polymers |
| EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US20100227799A1 (en) * | 2009-03-09 | 2010-09-09 | Medtronic Vascular, Inc. | Simultaneous photodynamic therapy and photo induced polymerization |
| WO2010120552A2 (en) | 2009-04-01 | 2010-10-21 | Micell Technologies, Inc. | Coated stents |
| US8236341B2 (en) * | 2009-04-02 | 2012-08-07 | Medtronic Vascular, Inc. | Poly(tetrafluoroethylene) polymer with nitric oxide donating surface |
| US20100256728A1 (en) * | 2009-04-07 | 2010-10-07 | Medtronic Vascular, Inc. | Semi-Permiable Biodegradable Stent Graft and Uses Thereof |
| US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
| JP5719347B2 (ja) | 2009-04-16 | 2015-05-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌治療のための組成物及び方法 |
| EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
| WO2010132233A1 (en) | 2009-05-13 | 2010-11-18 | The Trustees Of The University Of Pennsylvania | Combination antineoplastic therapy |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| CN102770455B (zh) | 2009-08-03 | 2017-02-08 | 迈阿密大学 | 用于体内扩增调节性t细胞的方法 |
| EP2480557A2 (en) | 2009-09-25 | 2012-08-01 | Cadila Healthcare Limited | Process for the preparation of rapamycin derivatives |
| CN102574852B (zh) | 2009-10-23 | 2014-06-25 | 伊莱利利公司 | Akt抑制剂 |
| KR20120115237A (ko) | 2009-10-30 | 2012-10-17 | 어리어드 파마슈티칼스, 인코포레이티드 | 암 치료 방법 및 조성물 |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CN102933658A (zh) | 2009-12-18 | 2013-02-13 | 界面生物公司 | 从自组装涂层局部递送药物 |
| US8182830B2 (en) * | 2010-01-05 | 2012-05-22 | Medtronic Vascular, Inc. | Hydrogen sulfide generating polymers |
| JP2013518093A (ja) * | 2010-01-28 | 2013-05-20 | フレゼニウス・カビ・オンコロジー・リミテッド | テムシロリムスの製造のための改善された方法およびその中間体 |
| WO2011097103A1 (en) | 2010-02-02 | 2011-08-11 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
| US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| KR101620661B1 (ko) | 2010-04-27 | 2016-05-12 | 로슈 글리카트 아게 | 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법 |
| AU2011260016B2 (en) | 2010-06-02 | 2013-08-22 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of Rapamycin esters |
| CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
| US9321782B2 (en) | 2010-08-04 | 2016-04-26 | Meril Life Sciences Pvt. Ltd. | Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| JP2014503500A (ja) | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
| JP2014503499A (ja) | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく治療に適した被験体の事前選択 |
| PL2455104T3 (pl) | 2010-11-19 | 2013-12-31 | Univ Freiburg | Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG |
| CN102020662B (zh) * | 2011-01-07 | 2013-02-13 | 天津市炜杰科技有限公司 | 一种驮瑞塞尔制备方法 |
| CN103732226B (zh) | 2011-02-18 | 2016-01-06 | 诺瓦提斯药物公司 | mTOR/JAK抑制剂组合疗法 |
| US9051336B2 (en) | 2011-04-01 | 2015-06-09 | Sandoz | Regioselective acylation of rapamycin at the C-42 position |
| IN2013MN02170A (es) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| US8809562B2 (en) | 2011-06-06 | 2014-08-19 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| CN102424829B (zh) * | 2011-10-26 | 2013-10-16 | 苏州汉酶生物技术有限公司 | 一种酶催化合成坦西莫司的方法 |
| KR20170049617A (ko) | 2011-12-16 | 2017-05-10 | 화이자 인코포레이티드 | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 |
| GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| CN102796115B (zh) * | 2012-05-25 | 2015-07-15 | 上海现代制药股份有限公司 | 一种坦西莫司的制备方法 |
| US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
| CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| AU2013331440A1 (en) | 2012-10-16 | 2015-04-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| EP2943253B1 (en) | 2013-01-09 | 2021-10-20 | University Of Miami | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2 |
| ES2758227T3 (es) | 2013-02-15 | 2020-05-04 | Univ California | Receptor de antígeno quimérico y métodos de uso del mismo |
| KR20150143476A (ko) | 2013-03-12 | 2015-12-23 | 미셀 테크놀로지즈, 인코포레이티드 | 생흡수성 생체의학적 임플란트 |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| EP2968370A4 (en) | 2013-03-14 | 2016-09-21 | Univ Maryland | AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF |
| US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
| WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| CN103421023B (zh) * | 2013-07-30 | 2015-09-23 | 福建省微生物研究所 | 一种替西罗莫司的合成工艺 |
| BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| US10428331B2 (en) | 2014-01-16 | 2019-10-01 | Musc Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2015237200A1 (en) | 2014-03-27 | 2016-10-06 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CA2950589A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016014576A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN104086564B (zh) * | 2014-07-30 | 2019-02-05 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| RU2724999C2 (ru) | 2014-08-19 | 2020-06-29 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| CN113620978A (zh) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP2997977A1 (en) | 2014-09-19 | 2016-03-23 | Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe | Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US20190054117A1 (en) | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
| US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
| IL258574B1 (en) | 2015-11-11 | 2024-09-01 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and their uses |
| US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| CA3035774A1 (en) | 2016-09-22 | 2018-03-29 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
| TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
| TW201825090A (zh) | 2016-11-23 | 2018-07-16 | 瑞士商諾華公司 | 增強免疫反應之方法 |
| EP3576736A4 (en) | 2017-02-10 | 2020-08-26 | Torcept Therapeutics Inc. | RAPAMYCIN ANALOGUE |
| SG11201907814SA (en) | 2017-03-03 | 2019-09-27 | F1 Oncology Inc | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3624863B1 (en) | 2017-05-15 | 2021-04-14 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| CN108948045A (zh) * | 2017-05-20 | 2018-12-07 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的制备方法 |
| CN110996687A (zh) | 2017-05-26 | 2020-04-10 | 墨卡托医疗系统公司 | 用于治疗再狭窄的联合疗法 |
| US20200129486A1 (en) | 2017-06-26 | 2020-04-30 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
| EP3652306A1 (en) | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN110382019B (zh) | 2018-03-14 | 2020-08-25 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械和医疗方法 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788050B1 (en) | 2018-05-01 | 2024-08-28 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
| IL300091A (en) | 2018-05-01 | 2023-03-01 | Revolution Medicines Inc | C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| CN112638436A (zh) | 2018-05-22 | 2021-04-09 | 界面生物公司 | 用于将药物递送至血管壁的组合物和方法 |
| CA3107349A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| CN113164557A (zh) | 2018-07-23 | 2021-07-23 | 因柯利尔疗法公司 | 治疗神经性病症的方法 |
| EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
| CN113164576A (zh) | 2018-10-05 | 2021-07-23 | 圣安娜儿童癌症研究中心 | 嵌合抗原受体(car)组 |
| EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| KR20210072797A (ko) | 2018-10-05 | 2021-06-17 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
| EP3632460A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| JP7262581B2 (ja) | 2018-11-14 | 2023-04-21 | ルトニックス，インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113939324A (zh) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | 在经改性装置表面上具有药物洗脱涂层的医疗装置 |
| CN114007665A (zh) | 2019-04-11 | 2022-02-01 | 因柯利尔疗法公司 | 改善脑脊液的方法及其装置和系统 |
| CN113372359A (zh) * | 2020-03-10 | 2021-09-10 | 鲁南制药集团股份有限公司 | 一种坦西莫司的制备方法 |
| CA3200514A1 (en) | 2020-11-03 | 2022-05-12 | Rdiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
| EP4370160A1 (en) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
| WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
| WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4375464A (en) * | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| NO921449L (no) | 1991-04-17 | 1992-10-19 | American Home Prod | Karbamater av rapamycin |
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
| US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5169851A (en) * | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
-
1994
- 1994-04-18 US US08/229,261 patent/US5362718A/en not_active Ceased
- 1994-11-08 TW TW083110308A patent/TW275631B/zh not_active IP Right Cessation
-
1995
- 1995-03-29 IL IL113179A patent/IL113179A/en not_active IP Right Cessation
- 1995-04-13 ZA ZA953090A patent/ZA953090B/xx unknown
- 1995-04-14 DE DE122008000023C patent/DE122008000023I1/de active Pending
- 1995-04-14 BR BR9507323A patent/BR9507323A/pt active IP Right Grant
- 1995-04-14 CN CN95193325A patent/CN1059905C/zh not_active Expired - Lifetime
- 1995-04-14 SI SI9530648T patent/SI0763039T1/xx unknown
- 1995-04-14 HU HU9602893A patent/HU225915B1/hu active Protection Beyond IP Right Term
- 1995-04-14 SK SK1330-96A patent/SK281787B6/sk not_active IP Right Cessation
- 1995-04-14 CA CA002187024A patent/CA2187024C/en not_active Expired - Lifetime
- 1995-04-14 KR KR1019960705839A patent/KR100330800B1/ko active IP Right Grant
- 1995-04-14 AT AT02014322T patent/ATE350384T1/de active
- 1995-04-14 AT AT95915671T patent/ATE234307T1/de active
- 1995-04-14 EP EP95915671.2A patent/EP0763039B3/en not_active Expired - Lifetime
- 1995-04-14 PL PL95316948A patent/PL183178B1/pl unknown
- 1995-04-14 MX MX9604694A patent/MX9604694A/es unknown
- 1995-04-14 ES ES95915671.2T patent/ES2191704T7/es active Active
- 1995-04-14 DK DK95915671T patent/DK0763039T3/da active
- 1995-04-14 PT PT02014322T patent/PT1266899E/pt unknown
- 1995-04-14 RU RU96122172A patent/RU2134267C1/ru active
- 1995-04-14 DK DK02014322T patent/DK1266899T3/da active
- 1995-04-14 PT PT95915671T patent/PT763039E/pt unknown
- 1995-04-14 DE DE69535363T patent/DE69535363T2/de not_active Expired - Lifetime
- 1995-04-14 SI SI9530730T patent/SI1266899T1/sl unknown
- 1995-04-14 JP JP52710595A patent/JP3725901B2/ja not_active Expired - Lifetime
- 1995-04-14 WO PCT/US1995/004603 patent/WO1995028406A1/en active IP Right Grant
- 1995-04-14 EP EP02014322A patent/EP1266899B1/en not_active Expired - Lifetime
- 1995-04-14 AT AT06026307T patent/ATE537176T1/de active
- 1995-04-14 ES ES06026307T patent/ES2375730T3/es not_active Expired - Lifetime
- 1995-04-14 ES ES02014322T patent/ES2277975T3/es not_active Expired - Lifetime
- 1995-04-14 CZ CZ963052A patent/CZ284567B6/cs not_active IP Right Cessation
- 1995-04-14 NZ NZ283988A patent/NZ283988A/en not_active IP Right Cessation
- 1995-04-14 DE DE69529897.6T patent/DE69529897T3/de not_active Expired - Lifetime
- 1995-04-14 EP EP06026307A patent/EP1760083B1/en not_active Expired - Lifetime
-
1998
- 1998-11-24 HK HK98112275A patent/HK1011352A1/xx not_active IP Right Cessation
- 1998-11-24 HK HK03101048.7A patent/HK1048816B/zh not_active IP Right Cessation
-
2003
- 2003-05-13 LV LVP-03-47A patent/LV13038B/en unknown
- 2003-09-12 CY CY0300065A patent/CY2378B1/xx unknown
-
2008
- 2008-05-15 LU LU91438C patent/LU91438I2/fr unknown
- 2008-05-15 NL NL300348C patent/NL300348I2/nl unknown
- 2008-05-16 FR FR08C0018C patent/FR08C0018I2/fr active Active
- 2008-05-19 CY CY200800012C patent/CY2008012I2/el unknown
-
2013
- 2013-06-28 US US13/931,400 patent/USRE44768E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK281787B6 (sk) | Hydroxyestery rapamycínu, ich použitie, farmaceutická kompozícia s ich obsahom a spôsob ich prípravy | |
| US5233036A (en) | Rapamycin alkoxyesters | |
| DE69430586T2 (de) | Aminoalkanester von rapamycin | |
| US5221670A (en) | Rapamycin esters | |
| US5102876A (en) | Reduction products of rapamycin | |
| US5489680A (en) | Carbamates of rapamycin | |
| US5373014A (en) | Rapamycin oximes | |
| DE69521438T2 (de) | Rapamycin 42-oxime und hydroxylamine | |
| US5378696A (en) | Rapamycin esters | |
| US5252579A (en) | Macrocyclic immunomodulators | |
| KR100330799B1 (ko) | C-22환안정화된라파마이신유도체및이를함유하는약제학적조성물 | |
| MXPA96004694A (es) | Hidroxiesteres de rapamicina, proceso para supreparacion y composiciones farmaceuticas que loscontienen | |
| US5358944A (en) | Rapamycin esters for treating transplantation rejection | |
| WO1993005046A1 (en) | Aminodiesters of rapamycin | |
| HUT73418A (en) | Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds | |
| JPH05117279A (ja) | 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物 | |
| AU679854C (en) | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20150414 |
|
| SPCC | Change of address or name of an owner of an spc |
Owner name: WYETH LLC, US Spc suppl protection certif: 68 4-2008 Effective date: 20170322 |
|
| SPCE | Expiry of an spc |
Free format text: PRODUCT NAME: TEMSIROLIMUS Spc suppl protection certif: 68, 4-2008 Effective date: 20200415 |